Get started

Financials · ASMB

Assembly Biosciences Inc. (ASMB) financials

For the twelve months ended Jun 30, 2026, Assembly Biosciences Inc. reported $74.84M of revenue and -$42.0K of net income.

Revenue, TTM
$74.84M
Revenue growth, YoY
+125.1%
Net income, TTM
-$42.0K
Net margin
-0.1%
Free cash flow, TTM
-$38.57M
Cash
$32.29M
P/S
5.93
Market cap
$443.7M
Annual revenue$72.30M
FY2016FY2025
Annual net income-$6.12M
FY2016FY2025
Annual free cash flow-$41.16M
FY2016FY2025

ASMB revenue and earnings growth

ASMB revenueQ2 2026$13.37M

Quarter YoY
+38.9%
QoQ
+62.8%
FY YoY
+153.5%
5Y CAGR
-1.8%

ASMB revenue was $13.37M in fiscal Q2 2026 (ended Jun 30, 2026), up 38.9% from a year earlier and up 62.8% from the prior quarter. For the full fiscal 2025 it was $72.30M, up 153.5% from fiscal 2024. Compound annual growth was -1.8% over 5 years.

ASMB net incomeQ2 2026-$3.86M

ASMB net income was -$3.86M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$10.20M a year earlier. For the full fiscal 2025 it was -$6.12M, compared with -$40.18M in fiscal 2024.

ASMB EPSQ2 2026-$0.20

ASMB diluted EPS was -$0.20 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.55.

ASMB free cash flowQ2 2026-$15.49M

ASMB free cash flow was -$15.49M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$16.76M a year earlier. For the full fiscal 2025 it was -$41.16M, compared with -$51.15M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$72.30M$28.52M$7.16M$0$6.25M$79.11M$15.96M$14.80M$9.02M$0
Research and development$64.81M$55.93M$48.90M$69.98M$68.52M$106.82M$85.76M$72.74M$44.23M$33.09M
Selling, general and admin$19.61M$18.01M$22.91M$24.13M$28.78M$37.06M$32.92M$34.80M$17.02M$12.19M
Operating income-$12.12M-$45.42M-$64.65M-$94.11M-$132.69M-$64.78M-$102.71M-$92.73M-$52.23M-$45.28M
Pre-tax income-$6.12M-$39.85M-$61.20M-$93.09M-$132.39M-$62.15M-$98.41M-$89.65M-$51.86M-$44.88M
Income tax$0$330.0K$33.0K$0-$2.53M$0-$774.0K$1.10M-$9.05M-$618.0K
Net income-$6.12M-$40.18M-$61.23M-$93.09M-$129.85M-$62.15M-$97.63M-$90.75M-$42.81M-$44.26M
EPS, basic-$0.55-$6.69-$13.38-$23.08-$36.00-$21.00-$44.64-$47.76-$28.92-$30.84
EPS, diluted-$0.55-$6.69-$13.38-$23.08-$36.00-$21.00-$44.64-$47.76-$28.92-$30.84
Diluted shares11.2M6.0M4.6M4.0M3.6M3.0M2.2M1.9M1.5M1.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$58.45M$38.34M$19.84M$52.42M$45.63M$59.44M$46.73M$41.47M$82.03M$28.57M
Short-term investments-------$176.61M$37.91M$24.39M
Receivables$974.0K$0$43.0K$944.0K$336.0K$1.23M$3.37M$2.43M$2.27M$0
Current assets$254.55M$115.50M$133.79M$96.97M$154.20M$224.49M$282.78M$222.50M$123.12M$53.57M
Goodwill-----$12.64M$12.64M$12.64M$12.64M$12.64M
Total assets$257.59M$119.17M$136.82M$101.79M$191.06M$283.25M$339.91M$268.05M$169.30M$98.12M
Current liabilities$48.78M$47.80M$39.23M$16.30M$16.07M$24.43M$24.44M$18.47M$13.49M$7.12M
Total liabilities$50.84M$85.81M$95.73M$19.13M$22.13M$42.68M$66.69M$57.39M$56.18M$18.24M
Shareholders' equity$206.75M$33.36M$41.10M$82.66M$168.93M$240.58M$273.22M$210.65M$113.12M$79.88M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$41.09M-$51.12M$22.74M-$84.46M-$93.40M-$62.96M-$84.07M-$64.96M$1.86M-$34.88M
Capital expenditures$66.0K$28.0K$255.0K$102.0K$3.10M$470.0K$1.55M$340.0K$865.0K$147.0K
Free cash flow-$41.16M-$51.15M$22.49M-$84.56M-$96.49M-$63.43M-$85.62M-$65.30M$995.0K-$35.03M
Investing cash flow-$113.47M$40.17M-$69.14M$90.64M$26.52M$68.07M-$50.32M-$135.40M-$15.64M$36.20M
Financing cash flow$174.67M$29.45M$13.82M$614.0K$53.06M$7.60M$139.65M$159.79M$67.24M$153.0K
Stock-based compensation$4.68M$3.12M$5.12M$6.59M$5.24M$21.85M$20.56M$28.48M$8.60M$5.02M
Depreciation and amortization$129.0K$129.0K$450.0K$498.0K$466.0K$691.0K$494.0K$643.0K$219.0K-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY153.5%298.2%--100.0%-92.1%395.6%7.8%64.1%--
Operating margin-16.8%-159.3%-902.5%--2121.7%-81.9%-643.4%-626.4%-579.1%-
Net margin-8.5%-140.9%-854.8%--2076.4%-78.6%-611.6%-613.0%-474.7%-
Free cash flow margin-56.9%-179.3%313.9%--1542.9%-80.2%-536.4%-441.1%11.0%-
Return on equity-3.0%-120.4%-149.0%-112.6%-76.9%-25.8%-35.7%-43.1%-37.8%-55.4%
Return on assets-2.4%-33.7%-44.7%-91.5%-68.0%-21.9%-28.7%-33.9%-25.3%-45.1%
Current ratio5.222.423.415.959.599.1911.5712.059.137.52

Source: XBRL data Assembly Biosciences Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-5, first reported Aug 14, 2014; 1-for-12, first reported Mar 28, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ASMB peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ASMB$74.84M+125.1%-$42.0K-0.1%$443.7M
VIR$302.80M+1696.0%-$184.79M-61.0%$2.34B
ABUS$181.72M+1078.8%$153.05M84.2%$569.4M
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
ALGS$5.83M+122.2%-$66.28M-1137.2%$24.7M

ASMB FAQ

7 questions
  • What is ASMB revenue?
    Assembly Biosciences Inc. (ASMB) reported $74.84M of revenue for the twelve months ended Jun 30, 2026. That is up 125.1% from the year before. Revenue for fiscal 2025 was $72.30M.
  • Is ASMB profitable?
    No. Assembly Biosciences Inc. reported a net loss of $42.0K for the twelve months ended Jun 30, 2026.
  • How much cash and debt does ASMB have?
    Assembly Biosciences Inc. reported $32.29M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ASMB revenue growing?
    Assembly Biosciences Inc.'s revenue changed +153.5% in fiscal 2025, to $72.30M. Its compound annual growth rate was -1.8% over 5 years.
  • What is ASMB free cash flow?
    Assembly Biosciences Inc. generated -$38.57M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$38.48M less capital expenditures.
  • When did ASMB last report financial results?
    The latest statements here come from Assembly Biosciences Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this ASMB financial data come from?
    Quantisnow builds these statements from the structured XBRL data Assembly Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.